In India, it has been figured out that 1 in 6 adults live with Diabetes. India ranks number 2 among the top 10 leading countries with Diabetes and it is reckoned as the diabetes capital of the world. Type 2 diabetes is the chief risk factor to cause cardiovascular complications which leads to increase in mortality and morbidity rates. In recent years, the development of newer class of antidiabetic agents such as SGLT2 inhibitors have been proven to be favourable for diabetic patients and many number of theories have been put forwarded to proclaim the cardioprotective potential of SGLT2 inhibitors. In our study we assessed the cardiovascular outcomes of SGLT 2 inhibitors in Type 2 Diabetes Mellitus patients with Cardiovascular risk. Method- We conducted a meta analysis based on multicentric randomized placebo- controlled trials of three SGLT2 Inhibitors namely Empagliflozin,Dapagliflozin and Ertugliflozin.The statistical analysis was done using Revman statistical software and risk ratios with 95% confidence interval were obtained. Results- A total of 32,426 participants with type 2 diabetes were included in our Meta analysis. We identified that the SGLT 2 inhibitors can potentially protect the Type 2 DM patients against the cardiovascular events like hospitalization for Heart failure and 3 point MACE.

Keywords : DM=Diabetes mellitus, CVD=cardiovascular disease,SGLT2=Sodium–Glucose linked Cotransporter 2,MACE=major adverse cardiovascular events,HHF=hospitalization for heart failure,RR= risk ratio or relative risk ,PICO = Patient/population I=Intervention C=comparator O=outcomes,PRISMA= preferred reporting items for systematic reviews.